Obicetrapib (Monash University and NewAmsterdam Pharma) is an oral selective cholesteryl ester transfer protein (CETP) inhibitor being developed for dyslipidemia. Patients with high cardiovascular risk typically aim to lower cholesterol with a combination of statins, diet, and exercise, but this is often not enough . A foundational [...]
4 minute read
Sep. 28, 2022
Obicetrapib: an Oral Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor for Dyslipidemia
obicetrapib
oral CETP inhibitor Ph. III candidate in cardiology Signif. lipid lowering effect at 5 mg PO QD Nat. Med. NewAmsterdam Pharma B.V., Naarden, NL (Amgen)